Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepofarsen in Leber Congenital Amaurosis (LCA10)
NCT06891443Phase 3Recruiting
- Sponsor
- Laboratoires Théa
- Start
- Jun 2025
- Primary completion
- Nov 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of sepofarsen in Leber congenital amaurosis (LCA) (7 arms), sponsored by Laboratoires Théa. Primary endpoint: Best-Corrected Visual Acuity at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
sepofarsen
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT06891443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891443.